Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient.
The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the
virus to their babies was pivotal to the prevention of AIDS and so along the same lines the
investigators will test the hypothesis that 14 days of the anti-viral Valganciclovir (VAL) to
kidney donors prior to the transplant compared to placebo will reduce EBV and CMV viremia in
the 1st year posttransplant in pediatric kidney recipients.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute